Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team
2010年8月30日 - 8:30PM
Easton Pharmaceuticals (Pink Sheets:EAPH), a specialty
pharmaceutical company that designs, develops, and markets a
premium array of topically delivered therapeutic healthcare
products, announced today that Lee Hendelson has agreed to join the
company as Chief Financial Officer. An Accountant, CFO and
Controller for various companies during the past 35 years, Mr.
Hendelson will provide direction for all financial matters for
Easton Pharmaceuticals in his capacity as Chief Financial Officer.
"As a public company, we are extremely pleased to have someone
with Lee's solid experience as CFO," says John Easton, Easton
Pharmaceuticals' Chairman of the Board. "He will help guide us
through all the necessary regulatory filings and financial issues,
and we will also be able to leverage many of Lee's proven
skill-sets to move Easton Pharmaceuticals forward to success."
Mr. Hendelson played an integral part in the financial
management of, and preparation and filings of financial statements
for various publicly traded companies, and worked closely with
various venture capital firms in New York City and Palm Beach,
Florida analyzing profitability for portfolio clients. Prior to
joining Easton Pharmaceuticals, Mr. Hendelson built a successful
accounting firm in the United States, providing specialized
accounting services, tax problem resolution, tax preparation for
businesses and estates, due diligence, forecasting and pro-forma
financial statements for business plans. Mr. Hendelson attended The
City University of New York and received his Bachelors of Science
in Accounting.
About Easton Pharmaceuticals Inc.
Toronto-based Easton Pharmaceuticals is a specialty
pharmaceutical company that designs, develops, and markets a
premium array of topically delivered therapeutic healthcare
products. The company's proprietary gel formulation is an
innovative and unique transdermal delivery system. Easton
Pharmaceuticals' flagship product, VIORRA, is an over-the-counter
aid for the treatment of FSAD (Female Sexual Arousal Disorder).
VIORRA is a topical, daily-use product classified by the FDA as
containing Generally Regarded as Safe substances and ingredients.
For more information, visit http://www.eastonpharma.com
Copyright ©2010 Easton Pharmaceuticals Inc. All rights reserved.
Easton Pharmaceuticals, Easton Pharma and, the Easton
Pharmaceuticals logo, and all other Easton Pharmaceuticals company,
product, and services names and slogans are trademarks or
registered trademarks of Easton Pharmaceuticals Inc. Other names
and marks are the property of their respective owners.
This highest-value, lowest cost press release is a service of So
Act Network's Press Club. www.pressclub.biz
CONTACT: Easton Pharmaceuticals Inc.
Media relations:
(416) 619-0291
(347) 284-0192
Fax: +1(888) 877-3723
Media relations:
Media@eastonpharma.com
Investor relations:
IR@eastonpharma.com
info@eastonpharma.com
www.eastonpharma.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 12 2024 まで 1 2025
Easton Pharmaceuticals (CE) (USOTC:EAPH)
過去 株価チャート
から 1 2024 まで 1 2025